Melatoninand Cardiovascular Function

Krause, Diana N.; Geary, Greg G.; Doolen, Suzanne; Duckles, Sue Piper

doi:10.1007/0-306-46814-x_32

Cited by 23 publications

(19 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular System. A number of studies point to a role for melatonin in cardiovascular regulation (Krause et al, 1999). MT 1 and MT 2 protein and mRNA are expressed in peripheral and cerebral arteries of various species, including humans (Savaskan et al, 2001;Masana et al, 2002).…”

Section: B Melatonin Receptor Functionmentioning

confidence: 99%

International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors

et al. 2010

Self Cite

View full text Add to dashboard Cite

Section: B Melatonin Receptor Functionmentioning

confidence: 99%

International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors

et al. 2010

Self Cite

View full text Add to dashboard Cite

“…Melatonin also affects the cardiovascular system [12] and interacts with the immune system [13] . It has also been implicated in metabolic control [14] .…”

Section: Melatoninmentioning

confidence: 99%

Role of melatonin on diabetes-related metabolic disorders

Espino

Pariente²,

Rodríguez³

2011

WJD

103

View full text Add to dashboard Cite

Melatonin is a circulating hormone that is mainly released from the pineal gland. It is best known as a regulator of seasonal and circadian rhythms, its levels being high during the night and low during the day. Interestingly, insulin levels are also adapted to day/night changes through melatonin-dependent synchronization. This regulation may be explained by the inhibiting action of melatonin on insulin release, which is transmitted through both the pertussis-toxin-sensitive membrane receptors MT1 and MT2 and the second messengers 3',5' -cyclic adenosine monophosphate, 3',5'-cyclic guanosine monophosphate and inositol 1,4,5-trisphosphate. Melatonin may influence diabetes and associated metabolic disturbances not only by regulating insulin secretion, but also by providing protection against reactive oxygen species, since pancreatic β-cells are very susceptible to oxidative stress because they possess only low-antioxidative capacity. On the other hand, in several genetic association studies, single nucleotide polymorphysms of the human MT2 receptor have been described as being causally linked to an elevated risk of developing type 2 diabetes. This suggests that these individuals may be more sensitive to the actions of melatonin, thereby leading to impaired insulin secretion. Therefore, blocking the melatonin-induced inhibition of insulin secretion may be a novel therapeutic avenue for type 2 diabetes.

show abstract

“…Melatonin also affects the cardiovascular system [23] and interacts with the immune system [24]. It has also been implicated in metabolic control [25].…”

Section: Physiological Effects Of Melatoninmentioning

confidence: 99%

Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene

et al. 2009

View full text Add to dashboard Cite

Melatonin is a circulating hormone that is primarily released from the pineal gland. It is best known as a regulator of seasonal and circadian rhythms; its levels are high during the night and low during the day. Interestingly, insulin levels also exhibit a nocturnal drop, which has previously been suggested to be controlled, at least in part, by melatonin. This regulation can be explained by the proposed inhibitory action of melatonin on insulin release. Indeed, both melatonin receptor 1A (MTNR1A) and MTNR1B are expressed in pancreatic islets. The role of melatonin in the regulation of glucose homeostasis has been highlighted by three independent publications based on genome-wide association studies of traits connected with type 2 diabetes, such as elevated fasting glucose, and, subsequently, of the disease itself. The studies demonstrate a link between variations in the MTNR1B gene, hyperglycaemia, impaired early phase insulin secretion and beta cell function. The risk genotype predicts the future development of type 2 diabetes. Carriers of the risk genotype exhibit increased expression of MTNR1B in islets. This suggests that these individuals may be more sensitive to the actions of melatonin, leading to impaired insulin secretion. Blocking the inhibition of insulin secretion by melatonin may be a novel therapeutic avenue for type 2 diabetes.

show abstract

Melatoninand Cardiovascular Function

Cited by 23 publications

References 42 publications

International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors

International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors

Role of melatonin on diabetes-related metabolic disorders

Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene

Contact Info

Product

Resources

About